7-2013

High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN) *In Vitro* Analysis and Reporting Tool

Charles J. Woodrow
University of Oxford, charlie@tropmedres.ac

Sabina Dahlström
Hôpital Bichat-Claude Bernard

Richard Cooksey
University of Oxford

Jennifer A. Flegg
University of Oxford

Hervé Le Nagard
Université Paris Diderot

See next page for additional authors

AAC Journals.ASM.org

High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN) *In Vitro* Analysis and Reporting Tool

Charles J. Woodrow,[a,b] Sabina Dahlström,[c] Richard Cooksey,[a] Jennifer A. Flegg,[a] Hervé Le Nagard,[d] France Mentré,[d] Claribel Murillo,[e] Didier Ménard,[f] François Nosten,[g] Kanlaya Sriprawat,[g] Lise Musset,[h] Neils B. Quashie,[i,j] Pharath Lim,[k,l] Rick M. Fairhurst,[k] Sam L. Nsobya,[m] Veronique Sinou,[n] Harald Noedl,[o] Bruno Pradines,[p,q,r] Jacob D. Johnson,[s] Philippe J. Guerin,[a] Carol H. Sibley,[a,t] Jacques Le Bras[c,u,v]

WorldWide Antimalarial Resistance Network (WWARN), Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom[a]; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand[b]; WorldWide Antimalarial Resistance Network (WWARN) In Vitro Module, Hôpital Bichat-Claude Bernard, Paris, France[c]; INSERM, Université Paris Diderot, UMR-S 738, Paris, France[d]; International Center for Medical Research and Training (CIDEIM), Cali, Colombia[e]; Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia[f]; Shoklo Malaria Research Unit, Mae Sod, Tak, Thailand[g]; Laboratoire de Parasitologie, Centre National de Référence de la Chimiorésistance du Paludisme pour la Région Antilles-Guyane, Institut Pasteur de la Guyane, Cayenne, French Guiana[h]; Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School,[i] and Epidemiology Department, Noguchi Memorial Institute for Medical Research, University of Ghana,[j] Accra, Ghana; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA[k]; National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia[l]; Department of Medicine, Makerere University, Kampala, Uganda[m]; Aix-Marseille Université, UMR-MD3, Marseille, France[n]; Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria[o]; Unité de Parasitologie, Institut de Recherche Biomédicale des Armées, Marseille, France[p]; Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France[q]; Centre National de Référence du Paludisme, Marseille, France[r]; U.S. Army Medical Research Unit—Kenya, Walter Reed Project, Kisumu, Kenya[s]; Department of Genome Sciences, University of Washington, Seattle, Washington, USA[t]; Université Paris Descartes (Paris 5), Paris, France[u]; Institut de Recherche pour le Développement (IRD), UMR 216, Paris, France[v]

Assessment of *in vitro* susceptibility is a fundamental component of antimalarial surveillance studies, but wide variations in the measurement of parasite growth and the calculation of inhibitory constants make comparisons of data from different laboratories difficult. Here we describe a Web-based, high-throughput *in vitro* analysis and reporting tool (IVART) generating inhibitory constants for large data sets. Fourteen primary data sets examining laboratory-determined susceptibility to artemisinin derivatives and artemisinin combination therapy partner drugs were collated from 11 laboratories. Drug concentrations associated with half-maximal inhibition of growth (IC_{50}s) were determined by a modified sigmoid E_{max} model-fitting algorithm, allowing standardized analysis of 7,350 concentration-inhibition assays involving 1,592 isolates. Examination of concentration-inhibition data revealed evidence of apparent paradoxical growth at high concentrations of nonartemisinin drugs, supporting amendment of the method for calculating the maximal drug effect in each assay. Criteria for defining more-reliable IC_{50}s based on estimated confidence intervals and growth ratios improved correlation coefficients for the drug pairs mefloquine-quinine and chloroquine-desethylamodiaquine in 9 of 11 and 8 of 8 data sets, respectively. Further analysis showed that maximal drug inhibition was higher for artemisinins than for other drugs, particularly in ELISA (enzyme-linked immunosorbent assay)-based assays, a finding consistent with the earlier onset of action of these drugs in the parasite life cycle. This is the first high-throughput analytical approach to apply consistent constraints and reliability criteria to large, diverse antimalarial susceptibility data sets. The data also illustrate the distinct biological properties of artemisinins and underline the need to apply more sensitive approaches to assessing *in vitro* susceptibility to these drugs.

The mission of the WorldWide Antimalarial Resistance Network (WWARN) is to enhance the quality, quantity, and geographic extent of drug susceptibility data available to the malaria control community via a global data repository. Laboratory-based assessment of parasites in culture ("*in vitro*") enables measurement of the intrinsic drug susceptibility of *Plasmodium falciparum* without the confounding effects of host pharmacokinetics, immunity, and genetics (1). Parasites with reduced antimalarial susceptibilities can be established in continuous culture, allowing the investigation of molecular mechanisms of resistance as well as the assessment of susceptibility to other antimalarial agents (2). In an era when artemisinin combination therapies (ACTs) are recommended treatment for falciparum malaria worldwide, additional considerations apply. While the use of a combination is beneficial in therapeutic terms, resistance to either partner alone can develop without an immediate reduction in clinical treatment efficacy. Assessment of drug susceptibility in parasites isolated directly from patients provides an opportunity to detect resistance to each individual drug at a relatively early stage, potentially allowing appropriate action before clinically relevant drug failure occurs (1).

Received 21 November 2012 Returned for modification 27 December 2012
Accepted 18 April 2013
Published ahead of print 22 April 2013
Address correspondence to Charles J. Woodrow, charlie@tropmedres.ac.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.02350-12.

doi:10.1128/AAC.02350-12

TABLE 1 Data sets examined

Data set	Method[a]	Location	No. of isolates	Yr	Sample-to-culture delay (h)	Artemisinin(s)[b]	Partner(s)[c]	Other drug(s)[d]	No. of drug-free controls per plate	Reference[e]
A	^{3}H (0)	Madagascar	315	2006–2007	24–48	DHA	DQ, MQ	CQ, QN	3 or 12	17
B	^{3}H (0)	Travelers[f]	421	2010	4–48	DHA	DQ, LUM, MQ	CQ, QN	4–8	18
C	^{3}H (0)	French Guiana	83	2008	12–48	AM, AS, DHA	DQ, LUM, MQ	CQ, QN	2–4	19
D	^{3}H (24)	Thailand	42	2007	4–8	AS, DHA	LUM, MQ, PIP	CQ, QN	4	20
E	HRP2	Colombia	57	2006–2007	0–12	DHA	DQ, MQ	CQ	4	21
F	HRP2	Bangladesh	89	2008–2009	0–12	AS, DHA	MQ	CQ, QN	12	22
G	HRP2	Uganda	77	2010	1–6	DHA	DQ, LUM, PIP	CQ, QN	12	23
H	HRP2	Vietnam	48	2010–2011	2–48	DHA	DQ, LUM, MQ, PIP	CQ, QN	9 or 12	24
I	LDH	Senegal	104	2009	0–12	DHA	DQ, LUM, MQ	CQ, QN	9	25
J	LDH	Travelers[f]	195	2009	4–48	DHA	DQ, LUM, MQ	CQ, QN	4–8	18
K	LDH	Thailand	64	2009	4–8	DHA	LUM, MQ, PIP	CQ, QN	4	
L	SYBR	Cambodia	56	2010	18–24	DHA	MQ	CQ, QN	8	27
M	SMT	Colombia	57	2006–2007	0–12	DHA	DQ, MQ	CQ	4	21
N	SMT	Ghana	94	2010	0–6	AS	MQ	CQ, QN	12	26

[a] ^{3}H, isotopic hypoxanthine method (with the timing of addition of hypoxanthine [in hours] given in parentheses); SMT, schizont maturation test.
[b] DHA, dihydroartemisinin; AM, artemether; AS, artesunate.
[c] DQ, desethylamodiaquine; MQ, mefloquine; LUM, lumefantrine; PIP, piperaquine.
[d] CQ, chloroquine; QN, quinine.
[e] References are given for the descriptions of the methodology used at each site (not necessarily the specific data assessed).
[f] Samples that were obtained from returning travelers presenting to French hospitals and examined at the Centre National de Référence du Paludisme, Paris, France.

One challenge facing the *in vitro* field is that culture-based assessment of parasite susceptibility has undergone a natural evolution since techniques for studying chloroquine (CQ) resistance were established more than 4 decades ago (3). The basic measurement of drug susceptibility is the growth of parasites in the presence of a range of concentrations of a given drug, expressed as the concentration of the drug needed to suppress growth to 50% of that observed in the absence of the drug (50% inhibitory concentration [IC_{50}]). A wide variety of readout methods for assessing parasite growth have been described (4, 5), including microscopic assessment (6), incorporation of radiolabeled hypoxanthine (7), production of the highly expressed *P. falciparum* proteins lactate dehydrogenase (LDH) (8, 9) and histidine-rich protein 2 (HRP2) (10), and methods involving DNA detection, such as SYBR green fluorescence (11, 12) and flow cytometry (13). This variety of techniques reflects practical and financial considerations that define a specific need for different assays in different settings.

All methods for phenotyping parasite responses outside the host are to some degree surrogates for *in vivo* phenomena, and although each new technique has been validated against a standard (generally hypoxanthine incorporation), differences between the methods clearly exist. Longitudinal estimates from the same lab measured consistently over time are still informative (2, 4), but the comparison of data from different laboratories remains a major challenge. The use of control reference clones holds the potential to reduce this problem (2) but has rarely been achieved over a substantive time frame.

Differences in computational methods also compromise the comparison of results from different laboratories. Investigators calculate inhibitory constants by a variety of means, including algorithms within software packages and freely available tools based on log probit (14), polynomial (10), and sigmoid inhibition (15) models. In addition, some assays exhibiting poor growth are misleading and should not be used as a basis for defining drug resistance (4, 15). Standardized methods to address these issues have been reported on occasion (16), but in general, the classification of concentration-inhibition curves remains a time-consuming and potentially subjective process involving visual inspection of individual curves. The need to examine parasites isolated directly from patients precludes repeated studies of individual parasite isolates, further compounding these difficulties.

This work describes the development of an *in vitro* analysis and reporting tool (IVART) capable of producing inhibitory constants for large *in vitro* data sets in a rapid, automated manner via a Web interface. We first sought biological evidence to better define key elements of this tool and therefore collated a wide-ranging collection of raw data obtained in a variety of global locations, generating perhaps the most diverse data set of this type so far assembled. Systematic examination of concentration-inhibition data from this range of different assay readouts and drugs informed the choice of appropriate constraints for use in curve fitting. Criteria for defining a core subset of more-reliable assays were tested by examining correlation coefficients for IC_{50}s from pairs of drugs. The data also yielded biological insights into the distinct properties of artemisinin derivatives.

MATERIALS AND METHODS

Data sets used. Primary data sets describing the growth of *P. falciparum* in culture at varying drug concentrations in individual wells of 96-well plates were collated, allowing the comparison of data obtained using various assay methods (microscopic assessment, radiolabeled hypoxanthine uptake inhibition, HRP2 and *Plasmodium* LDH [pLDH] enzyme-linked immunosorbent assays [ELISA], and SYBR green). Three groups of drugs were studied: (i) artemisinins found in ACTs, consisting of dihydroartemisinin (DHA), artemether (AM), and artesunate (AS); (ii) ACT partner drugs (or active metabolites) desethylamodiaquine (DQ), lumefantrine (LUM), mefloquine (MQ), and piperaquine (PIP); and (iii) chloroquine (CQ) and quinine (QN), drugs that are no longer recommended for first-line treatment of *P. falciparum* malaria. Data sets describing at least 40 parasite isolates were considered large enough to be included in this analysis. Fourteen data sets from 11 laboratories fulfilled these criteria (Table 1). The laboratory methodologies for many of these studies have been described previously (17–27). The primary growth outputs from assays



FIG 1 Example of growth inhibition data for dihydroartemisinin (DHA) and mefloquine (MQ), obtained by a tritiated-hypoxanthine incorporation assay of a sample from a traveler studied at the Centre National de Référence du Paludisme, Paris, France. In this case, a paradoxical increase in apparent growth is observed at higher concentrations of mefloquine (MQ) but not DHA. This phenomenon results in two distinct parameters of drug efficacy for MQ (see Table S1 in the supplemental material).

were formatted as uniform 12-by-8 96-well plate layouts in spreadsheets to facilitate automated processing and analysis.

Analysis of constraints for curve fitting. The levels of uninhibited and maximally inhibited growth are key parameters in IC_{50} calculations. For example, in the sigmoid E_{max} model, these levels represent the upper and lower asymptotes of the concentration-inhibition curve, where E_{max} is defined as the difference between these two measures of growth. The concentration-inhibition curve can be left unconstrained at its upper and lower ends (i.e., a 4-parameter model), particularly with large numbers of points, but for antimalarial susceptibility studies, this is frequently not practical, since the small number of drug concentrations used (in many cases, only 7) can produce highly unstable estimates. The upper (baseline growth without the drug) and lower (minimum growth) values were therefore constrained prior to modeling. Given the variability in experimental design and plate layout in the data sets examined, the upper growth constraint for each set of drug concentration-growth data [i.e., the baseline level of uninhibited growth, $G(C_0)$] (see Table S1 in the supplemental material) was defined as the average growth in all drug-free wells on the same plate.

Assessment of an appropriate means of determining the lower growth constraint involved systematic examination of concentration-inhibition data from a range of data sets. This approach took into account the biological reality that growth at the highest drug concentration, $G(C_{max})$, does not always correspond to the maximum drug effect because of a paradoxical rise in the growth measured at very high drug concentrations (Fig. 1), a phenomenon that has been noted previously (15). To explore this issue further, we prospectively defined two measurements of growth reduction (see Table S1 in the supplemental material) providing distinct measures of drug efficacy: R_{max1}, calculated as $G(C_0) - G(C_{max})$, and the modified measure of efficacy R_{max2}, calculated as $G(C_0) - G_{min}$, where G_{min} is defined as the mean growth at the two concentrations ranked as having the lowest mean growth in the concentration-inhibition series.

A pooled analysis of possible factors associated with the occurrence of an apparent paradoxical increase in growth at high drug concentrations was undertaken; this effect was considered to be present when R_{max1}/R_{max2} was <0.9 (a $>10\%$ rise in apparent growth over that at intermediate drug concentrations). The roles of the drug and the assay methodology were explored using a random-effects model (Stata, version 11.1; StataCorp), with the drug and the method as fixed effects and the site as a random effect (due to the heterogeneity between sites). Since it was suspected from initial observations that this phenomenon was associated with drugs that are relatively inactive against ring-stage parasites, DHA was used as the reference group for the drug; it was also the most commonly assayed antimalarial drug in current use (1,391 assays across 13 of the 14 data sets). Hypoxanthine incorporation was defined as the reference method.

High-throughput estimation of IC_{50}s. Curve fitting was undertaken using a sigmoid E_{max} model. In its general form, this model has four parameters: the IC_{50} (the 50% effective concentration [EC_{50}] for concentration-inhibition data), a measure of the curve's steepness at the IC_{50} (the sigmoidicity factor, or gamma), and the levels of uninhibited growth and maximally inhibited growth (see above).

Code from ICEstimator (15), based on the nls algorithm of R, which performs successive fittings of a sigmoid E_{max} model to concentration-inhibition data, was adapted within a Google Web Toolkit (GWT) Java-based Web application to perform data transformation, standardized analysis, and reporting of IC_{50}s for each data set. The details of ICEstimator have been described elsewhere (15). Briefly, the primary growth data are first converted to a percentage scale, with baseline growth (no drug) representing 100% and minimum growth (maximum drug inhibition) representing 0%. Following this conversion, the model is constrained at its upper and lower ends to 100% and 0%, respectively, and therefore produces only two parameters: the IC_{50} and the sigmoidicity factor (gamma). Initial values for the IC_{50} and gamma are determined by the point at which growth first falls below 50% of control growth (15, 18), and iterations are then undertaken until the limit of improvement is reached. In case of nonfitting (because of a weak dose-response relationship or a paucity of intermediate data points between 100% and 0%, as seen with a very steep slope), curve fitting is attempted again with gamma fixed at 10, based on a previous sensitivity analysis showing that gamma values greater than 10 would not significantly alter IC_{50}s in steep curves (15).

The sigmoid E_{max} model is focused primarily on determining the IC_{50} and the slope at this IC_{50}, and all other points on the modeled line are entirely determined by the IC_{50} and gamma. Points toward the ends of the curve, such as the IC_{90} and IC_{95}, frequently depart to some degree from the data observed, and for this reason, these values are potentially misleading and are not reported by IVART.

Assessment of criteria for defining a reliable subset of assays. It is generally recognized that at least 30% of parasite isolates placed in short-term culture exhibit less than optimal growth due to preexposure to drugs or other factors contributing to reduced parasite viability (4). To detect assays that are less reliable due to such factors, IVART was set up to calculate the ratio of the upper and lower 95% confidence intervals of the IC_{50} estimate, known as the confidence interval ratio (CIR). A threshold CIR of <3 was selected to define core assays of higher reliability for entry into pooled analyses and association studies. The CIR parameter is not useful in a subset of cases where modeling can be achieved only with a fixed gamma of 10, since this becomes a 1-parameter model, with inevitable narrowing of confidence intervals. For this subset of fixed-gamma assays, the growth ratio (uninhibited growth divided by maximally inhibited growth) was used to define core assays of higher reliability in accordance with previous recommendations (4). For each data set, the main subset of assays in which both the IC_{50} and gamma were successfully obtained was examined, and the proportion of assays with tight confidence intervals (CIR, <3) was determined at four levels of the growth ratio: <2, 2 to 3, 3 to 5, and >5.

The effect of applying reliability criteria was explored by examining intraisolate Pearson correlations of IC_{50}s for drug pairs in the whole data set and repeating this procedure with increasingly strict criteria.

Relative efficacies of artemisinins and partner drugs. Within the 12 nonmicroscopic data sets, the growth ratio (uninhibited growth divided by maximally inhibited growth) for each drug was compared to that for

DHA by using the Mann-Whitney test (with Bonferroni's correction for the number of drugs). The relative proportions of growth inhibition by DHA and MQ for individual parasite isolates, as illustrated in Fig. 1, were assessed by the Wilcoxon signed-rank test.

RESULTS

Constraints for curve fitting. The 14 data sets contained 7,350 individual drug inhibition assays. Analysis of growth inhibition characteristics revealed that 1,334 (18.1% of total) assays showed evidence of paradoxical growth at high concentrations (a rise in apparent growth of >10% over that at intermediate concentrations). Both the nature of the drug being tested and the readout methodology were clearly associated with this behavior. The four ACT partners (DQ, LUM, MQ, and PIP) were associated with a risk 2- to 3-fold greater (P, <0.001 in all cases) than that for the reference drug, DHA, while CQ and QN showed paradoxical effects at an intermediate level (P, <0.001 in both cases) (see Table S2 in the supplemental material). The phenomenon was seen less commonly with AS than with DHA. The assay method was also relevant; by using hypoxanthine incorporation as the reference group, a paradoxical increase in growth was most commonly encountered in assays based on LDH quantification by ELISA (odds ratio [OR], 1.27; P, 0.007). There was also a trend toward less-frequent occurrence in HRP2 and SYBR green assays that did not reach statistical significance. The issue was not encountered at all in assays assessing schizont maturation by microscopy.

These findings indicate that a paradoxical increase in growth measured at high drug concentrations reflects biological properties of antimalarial drugs rather than being simply an experimental artifact due to equipment or human error. For this reason, it was decided to amend the lower constraint of the sigmoid E_{max} model to G_{min} in order to provide a more accurate measure of maximum inhibition, avoiding underestimation of overall drug efficacy and spuriously low IC_{50}s.

Reliability criteria. The default criteria for defining a subset of more-reliable assays consisted of one main criterion, an IC_{50} confidence interval ratio (CIR) of <3. In the subset of curves with a fixed gamma (1,427 assays [19.4% of the total]), a growth ratio indicating a satisfactory signal/background ratio was used to assess reliability. As expected, there was a clear relationship between the growth ratio and the CIR in the 80.6% of assays where gamma was derived by modeling (i.e., 2-parameter models) (see Fig. S1 in the supplemental material). Growth ratios of 3 to 5 and >5 were associated with very high levels of assays with tight confidence interval ratios (across the 12 nonmicroscopic data sets, the median proportions with CIRs of <3 were 91.3% for a growth ratio of 3 to 5 and 95.3% for a growth ratio of >5). In contrast, a growth ratio of <2 was associated with relatively high proportions (median, 33.9%) of assays with uncertain IC_{50} estimates (CIR, >3). A growth ratio of 2 to 3 was generally associated with high levels of assays with tight confidence intervals (median proportion, 86.8%), but there did appear to be greater potential for less-reliable IC_{50} estimates to be accepted at this growth ratio level in hypoxanthine incorporation assays (see Fig. S1 in the supplemental material, data sets A and C).

The effect of applying reliability criteria was assessed by calculating the correlation between IC_{50}s for drug pairs within each data set, since it was predicted that application of increasingly strict criteria might improve correlation coefficients. MQ-QN and CQ-DQ provided the most powerful test cases given the number of data sets assessing each drug pair (11 and 8, respectively) and the strong, consistently documented associations between IC_{50}s for these drug pairs in field studies (20, 28–33). Exclusion of assays with CIRs of >3 and growth ratios of <2 (for assays with a fixed gamma) led to stronger correlations in 9/11 data sets for MQ-QN and in all 8 data sets for CQ-DQ (Fig. 2; see also Table S3 in the supplemental material). Statistical significance was generally maintained or strengthened in the more-reliable subset despite the reduction in sample size.

Increasingly strict classification of the fixed-gamma subset of assays, involving the exclusion of additional assays with growth ratios of <3 or <5 generally led to relatively small and inconsistent improvements in correlation (Fig. 2; see also Table S3 in the supplemental material). For hypoxanthine assays, where there was concern that unreliable assays might be accepted with growth ratios of 2 to 3 (see above), the mean proportion of additional isolates excluded in this range ranged from 1.8 to 5.1% in the four data sets (examining all drug pairs). The effects of various levels of exclusion criteria in hypoxanthine assays (drug pairs MQ-QN and CQ-DQ) are illustrated in Fig. S2 in the supplemental material.

IVART was therefore set to apply a default growth ratio of 2 to classify the subset of curves with a fixed gamma. When this default growth ratio was combined with the main criterion of a CIR of <3, 6,158 of 7,350 curves (83.8%) met the IVART core criteria.

Relative efficacies of artemisinins and partner drugs. Using only data that conformed to the default IVART reliability criteria (see above), it was possible to discern clear patterns in terms of the growth ratio depending on the assay and the drug (Fig. 3). For example, hypoxanthine-based assays showed the highest growth ratios (typically 5- to 15-fold reductions in growth), while protein-based and SYBR green assays had substantially lower growth ratios (i.e., relatively higher background values). Furthermore, nonartemisinin drugs tended to show lower growth ratios than artemisinin derivatives, an effect more marked with ELISA-based assays.

This issue was explored in more detail by examining the proportion of growth that could be inhibited $\{[G(C_0) - G_{min}]/G(C_0)\}$ (Fig. 1) by DHA compared to MQ for individual parasite isolates for which both assays passed the core criteria. In all 11 data sets with data for both drugs, MQ inhibited growth significantly less than DHA (P, <0.01 by the Wilcoxon signed-rank test), but the extent of this effect ranged from 1.0 to 30.2% (median values) across data sets (Fig. 4). ELISA-based assays showed substantially greater differences than those based on hypoxanthine incorporation or SYBR green fluorescence.

IVART online. The modeling approaches, constraints, and core criteria described above were adopted within an online version of IVART that is now available for external use at http://www.wwarn.org/toolkit/data-management/ivart. After a one-time registration process, users have access to the tool via a personalized interface that provides secure upload and storage of primary data in a 96-well plate format. IVART incorporates a "Plate Assistant" function to verify data layout and drug concentration information and then undertakes a single-pass analysis that produces graphical (Fig. 5) and spreadsheet reports for each individual assay, along with summaries of reliable-assay subsets by drug and year of study.

The range of drug concentrations in tests can also affect the calculated IC_{50}. In some data sets, the lowest concentration of the drug tested demonstrated more than 50% inhibition, suggesting



FIG 2 Effects of differing reliability criteria on interdrug correlation. Each series of interconnected symbols represents the Pearson correlation coefficients for chloroquine-desethylamodiaquine (CQ-DQ) (8 data sets) and mefloquine-quinine (MQ-QN) (11 data sets). Three levels of exclusion criteria were studied: [a], default IVART criteria; [b], IVART criteria with additional exclusion of fixed-gamma assays with a growth ratio of 2 to 3; [c], IVART criteria with additional exclusion of fixed-gamma assays with a growth ratio of 3 to 5. Filled triangles, significant ($P < 0.05$) correlation coefficients; open triangles, nonsignificant ($P > 0.05$) correlation coefficients. Individual correlation coefficients, *P* values, and numbers of samples are shown in Table S3 in the supplemental material.

that the drug concentration range tested was too high. Such assays still provide useful information on drug sensitivity (as long as they pass core criteria) but are marked in IVART with a "Range High" warning, because reassessment of the range of concentrations used in future assays may be indicated. Similarly, in some assays, growth inhibition appears to be incomplete, even at the highest drug concentration used. A "Range Low" warning is therefore displayed when the level of inhibition at the highest concentration of a drug is >10% greater than that at the next lowest concentration. Cautious interpretation of such assay data is required, since the effect may be explained by technical factors, such as underdosing of the drug in the wells or hemolysis of red blood cells, but such assays may also hint at emerging drug resistance.

DISCUSSION

A standardized approach to modeling *in vitro* data. Differences in laboratory and analytical practices complicate the comparison of data from antimalarial susceptibility assays obtained in different laboratories. This problem can potentially be reduced in a number of ways (2), including the use of validated reference clones (25, 34, 35) and quality-controlled drugs (36). IVART was developed to address a third source of variability by defining a single approach to the calculation of IC_{50}s that could be applied to primary data collected using a range of growth readout methods.

Examination of a wide range of data sets from 11 *in vitro* testing laboratories confirmed wide variations in experimental method and design. The number and identity of drugs being assessed differs across laboratories, presumably influenced by local patterns of clinical drug usage and susceptibility. This, in turn, affects the number and range of drug concentrations assessed, along with the number of no-drug control wells (critical for establishing a baseline for calculating IC_{50}s). In addition, some investigators select specific subsets of control wells from certain rows or columns for each drug, and control growth values may also be derived from wells containing low drug concentrations if these produce higher apparent growth than drug-free wells for any reason. Other potential sources of variation include the use of different models for curve fitting and manual removal of individual points considered to be outliers.

We began the process of standardizing the calculation of IC_{50}s by selecting the sigmoid E_{max} nonlinear regression model for curve fitting, since this does not involve subjective decisions regarding the form of the inhibition curve (a potential requirement if a polynomial curve is used). The upper and lower bounds of the model were constrained; given the range of plate layouts employed by different investigators, the upper constraint was defined as the mean growth in all wells on the plate with no drug present. Although edge and cross-plate changes in growth have been reported (37), the use of this larger number of drug-free control wells provides a statistical advantage in terms of greater numbers.

Several approaches to defining a lower constraint for curve fitting of antimalarial susceptibility data have been described. In hypoxanthine incorporation assays, the signal in uninfected red blood cells can be used, while the background in ELISA-based assays can be obtained by measuring the baseline antigen present at the start of incubation. However, in practice, these parameters are rarely recorded, and growth at the highest drug concentration, $G(C_{max})$, is commonly used; for example, $G(C_{max})$ was the method of choice in the original description of the LDH ELISA (9). However, in the data sets examined here, the assumption that the highest concentration of a drug defines its greatest level of inhibition proved incorrect, since nearly one-fifth of assays showed a paradoxical increase in apparent growth at very high drug concentrations. This effect did not appear to be due simply to



FIG 3 Growth ratios in nonmicroscopic forms of readout according to drug. Boxes show medians, while quartiles and whiskers indicate ranges. Dark shaded boxes, artemisinin derivatives; light shaded boxes, ACT partner drugs; open boxes, chloroquine (CQ) and quinine (QN). Asterisks indicate significant reductions in the growth ratio from that with DHA (P, 0.05 by the Mann-Whitney test with Bonferroni's correction). Data sets are those listed in Table 1 and were obtained by measurement of hypoxanthine incorporation (A to D), HRP2 (E to H), LDH (I to K), or SYBR green (L). Only assays passing core criteria were included.



FIG 4 Difference in proportional inhibition of growth $\{[G(C_0) - G_{min}]/G(C_0)\}$ between dihydroartemisinin (DHA) and mefloquine (MQ) (as illustrated in Fig. 1). Medians and interquartile ranges are shown. Positive values indicate greater efficacy of DHA than of MQ. Data sets (indicated along the y axis) are those listed in Table 1 and were obtained by measurement of hypoxanthine incorporation (A to D), HRP2 (E to H), LDH (I to K), or SYBR green (L). Only assays passing core criteria were included.

noise or outlying values, since it was more marked with nonartemisinin drugs and ELISA-based readouts. One possible explanation for such paradoxical apparent growth at high drug concentrations is that drugs lacking a primary effect on the ring-stage parasite at standard pharmacological concentrations may nevertheless affect the ring-stage parasite in other ways, leading to altered transcriptional responses and increased protein production or nucleic acid uptake. Additional explanations include precipitation of the drug from the solution at high concentrations, plate edge effects (37), and mixed-clone infections (38). Whatever the mechanism of this higher apparent growth at high drug concentrations, the definition of maximum growth inhibition clearly needs to account for cases where maximum inhibition occurs at intermediate concentrations of a drug. Ranking of concentrations in terms of the degree of inhibition allowed the selection of a modified measure of maximal inhibition, based on average growth over the two concentrations with the lowest growth.

Systematic application of reliability criteria. Since a proportion of parasites adapt poorly to *in vitro* culture and provide misleading signals, investigators usually define a core subset of more-reliable assays for use in association studies and summary outputs.

Drug	IC_{50}	Lower CI	Upper CI	CI Ratio	Gamma	Meets Core Criteria
CQ	650.97	528.21	773.73	1.46	5.04	yes
DHA	0.58	0.51	0.64	1.25	2.73	yes
DQ	90.82	85.41	96.24	1.13	10.00	yes
LUM	0.42	0.35	0.48	1.40	2.26	yes
PIP	4.84	4.06	5.63	1.39	5.71	yes
QN	82.34	68.8	95.87	1.39	2.18	yes



FIG 5 Excerpt from an output PDF file showing results for a Ugandan sample tested with six drugs. IC_{50}s are given in nanomolar concentrations. Growth values for the zero-drug wells are plotted at the left-hand ends of the graphs (at 2 log units below the lowest drug concentration used) for display purposes.

The method for defining such assays is rarely described in publications, and when conducted at the level of the individual assay, the decision-making process is likely to be time-consuming and potentially subjective. A key aim of IVART was to promote an objective approach to be applied across whole data sets. IVART uses a confidence interval ratio (CIR) of the IC_{50} estimate as its main method of defining core assays: a CIR of <3 is considered to indicate a reliable assay. However, the CIR is not useful in a subset of assays where initial 2-parameter modeling of the concentration-inhibition data fails and a fixed gamma value of 10 is used (around 20% of all assays); in this scenario, other means of defining reliable assays are required. Measures of goodness of fit were not chosen as IVART's default criteria because of the clear evidence that in a proportion of assays, the biological properties of drug inhibition produce data that naturally deviate from the classical sigmoid concentration-inhibition curve (see above). Such assays may be robust in terms of signal but nevertheless produce poor scores in goodness-of-fit assessments and would tend to be inappropriately rejected.

Historically, the overall level of signal to background (uninhibited to maximally inhibited growth, known as the growth ratio) has been recommended as a means of defining reliable curves (4). Examination of the relationship between the growth ratio and the confidence interval ratio across the data sets indicated that a threshold growth ratio of 2 would lead to acceptance of very few unreliable assays for ELISA- and SYBR green-based assays, and this was adopted within the default criteria of IVART. However, it was noted that there was a greater potential to accept less-reliable data in hypoxanthine-based assays, where the signal-to-background ratio is usually much higher than 2. This is also consistent with previous suggestions for reliability criteria in hypoxanthine-based studies, for which a growth ratio of 5 was proposed (4). In this study, when more-restrictive criteria were applied in hypoxanthine-based data sets, leading to the exclusion of assays with growth ratios of <3 or <5, relatively few additional isolates were excluded (since such growth ratios are rarely encountered in hypoxanthine-based data sets, and the growth ratio is applied only to the minority fixed-gamma subset). Accordingly, the correlation

coefficients for MQ-QN and CQ-DQ did not, on the whole, improve with these more-stringent criteria.

IVART was not designed with assays based on microscopic assessment in mind, since the use of microscopy-based methods to assess growth is decreasing. For all the drugs described here, growth inhibition should be complete at high drug concentrations, so the issues of determining maximal inhibition and the use of the growth ratio (usually infinity in schizont maturation experiments) to define reliable assays under certain circumstances do not apply. Nevertheless, the tool may be useful to laboratories continuing to use this methodology provided these issues are appreciated.

Distinctive properties of artemisinin derivatives. The high-throughput nature of IVART provided a unique opportunity to undertake a systematic examination of growth characteristics across a range of drugs and readout methods. As well as informing the design of IVART itself, this process provided additional biological insights informative for the future design and interpretation of *in vitro* antimalarial susceptibility studies. There was clear evidence that artemisinin derivatives show higher efficacy (i.e., inhibition of growth) than ACT partner drugs; for example, DHA inhibited a significantly greater proportion of growth than MQ in all sets of assays. This finding is consistent with the earlier onset of action of artemisinins, at the ring stage of parasite development (39–41), but the fact that this property is substantially greater in ELISA-based readouts had not been documented previously. The most likely reason for this is that both LDH and HRP2 are produced in significant quantities by ring-stage parasites (42), while hypoxanthine and SYBR green signals accumulate only at more-mature stages of asexual parasite development. There also appeared to be an effect of site, possibly reflecting the critical role of the timing of drug exposure in relation to the parasite stage. In locations with substantial delays between the removal of the sample from the patient and the setup of *in vitro* culture, parasites are more likely to first encounter the drug at mature stages, when they are susceptible to a wider range of compounds.

These observations prompt a reevaluation of how resistance is measured for different classes of antimalarial drugs. In the ACT era, assessment may require different approaches for artemisinins, which act rapidly against both the ring and mature stages, and ACT partner drugs, which act only against the more-mature stages of parasite development. The timing and duration of parasite-drug contact have been identified as important determinants of antimalarial susceptibility in the laboratory (2, 43), and specific methodologies and analyses for different applications are likely to provide more relevant information than a single method alone. Both the microscopic and hypoxanthine methods were developed in the era of slower-acting antimalarials with longer half-lives (CQ and MQ) (44); in these assays, ring-stage parasites contribute little signal (indeed, ring-stage growth is not assessed at all if hypoxanthine is added only after 24 h of incubation). In contrast, forms of artemisinin resistance reported from Southeast Asia (27, 45, 46) have been proposed to be confined to ring-stage parasites (47) and would not be predicted to influence susceptibility at the trophozoite or schizont stage. Short pulses of a drug during ring-stage growth have lasting growth-inhibitory effects (39–41, 48–52), and ring-stage pulse assays (in which relatively high concentrations of artemisinins are applied for relatively short periods) have been described recently (53, 54), providing the first clear view of ring-stage artemisinin resistance in parasites from western Cambodia (53). The need to remove a drug or to quantify ring-stage growth using a specific marker may present a challenge for widespread field use of this technique.

Summary and future work. IVART provides high-throughput, rapid, single pass analysis of *in vitro* sensitivity data, avoiding a variety of manual and potentially subjective processing steps currently in use. The tool can be applied to data sets obtained by a variety of methods and defines a subgroup of core IC_{50}s of greater reliability for pooled analyses and association studies. Its advantages, therefore, relate to consistency of approach and convenience.

The criteria suggested for accurate identification of a reliable subset of assays for use in association studies appear to be well suited to the signal-to-background properties of data sets from ELISA and SYBR green assays (methods increasingly used by *in vitro* testing laboratories); this is evidenced by substantially improved correlation scores for interdrug comparisons upon the application of these criteria. Nevertheless, ongoing monitoring of the tool's operation will be important in order to confirm prospectively that the approaches described are appropriate for further data sets from a variety of laboratories and methods. The handling of assays with sparse data around the IC_{50}, and consequently steep falls in growth between two drug concentrations, is a particular challenge for high-throughput approaches. Future incorporation of an additional algorithm that is better able to fit 2-parameter models to such data may provide a further advance, although this will require careful validation on a similarly representative data set. Large data sets of the type described here may also be used to develop mixed-effects modeling approaches to the analysis of concentration-inhibition data, involving a Bayesian framework for assessing whether individual *P. falciparum* isolates are resistant to a given drug.

ACKNOWLEDGMENTS

WWARN is supported by a Bill and Melinda Gates Foundation grant. This work was supported in part by the Intramural Research Program of NIAID, NIH.

We thank Carole Mackosso, Jeff Smith, Delia Bethell, and Ball Ekapirat for assistance with data acquisition and management, Sean Collins and Alberto Olliaro (WWARN) for design and programming of the IVART interface, Kasia Stepniewska (WWARN) and Sue Lee for statistical advice, and Bill Watkins and Ric Price for discussions.

REFERENCES

1. **Laufer MK, Djimde AA, Plowe CV.** 2007. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. **77:**160–169.
2. **Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE.** 2007. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar. J. **6:**120. doi:10.1186/1475-2875-6-120.
3. **Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD.** 1968. Effects of chloroquine, quinine, and cycloguanil upon the maturation of asexual erythrocytic forms of two strains of *Plasmodium falciparum* in vitro. Am. J. Trop. Med. Hyg. **17:**661–671.
4. **Basco LK.** 2007. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. WHO, Geneva, Switzerland.
5. **Noedl H, Wongsrichanalai C, Wernsdorfer WH.** 2003. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. **19:**175–181.
6. **Rieckmann KH, Campbell GH, Sax LJ, Mrema JE.** 1978. Drug sensitivity of *Plasmodium falciparum*. An in-vitro microtechnique. Lancet **i:**22–23.
7. **Desjardins RE, Canfield CJ, Haynes JD, Chulay JD.** 1979. Quantitative

assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. **16:**710–718.
8. **Piper R, Le Bras J, Wentworth L, Hunt-Cooke A, Houze S, Chiodini P, Makler M.** 1999. Immunocapture diagnostic assays for malaria using *Plasmodium* lactate dehydrogenase (pLDH). Am. J. Trop. Med. Hyg. **60:** 109–118.
9. **Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P.** 2001. A colorimetric in vitro drug sensitivity assay for *Plasmodium falciparum* based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am. J. Trop. Med. Hyg. **64:**233–241.
10. **Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C.** 2002. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob. Agents Chemother. **46:**1658–1664.
11. **Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, Roepe PD.** 2004. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob. Agents Chemother. **48:** 1807–1810.
12. **Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M.** 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. **48:**1803–1806.
13. **Malleret B, Claser C, Ong AS, Suwanarusk R, Sriprawat K, Howland SW, Russell B, Nosten F, Renia L.** 2011. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci. Rep. **1:**118. doi:10.1038/srep00118.
14. **Grab B, Wernsdorfer WH.** 1983. Evaluation of in vitro tests for drug sensitivity in *Plasmodium falciparum*: probit analysis of logdose/response test from 3–8 points assay. WHO, Geneva, Switzerland.
15. **Le Nagard H, Vincent C, Mentre F, Le Bras J.** 2011. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput. Methods Programs Biomed. **104:**10–18.
16. **Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ.** 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. **44:**3414–3424.
17. **Andriantsoanirina V, Ratsimbasoa A, Bouchier C, Jahevitra M, Rabearimanana S, Radrianjafy R, Andrianaranjaka V, Randriantsoa T, Rason MA, Tichit M, Rabarijaona LP, Mercereau-Puijalon O, Durand R, Menard D.** 2009. *Plasmodium falciparum* drug resistance in Madagascar: facing the spread of unusual *pfdhfr* and *pfmdr-1* haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob. Agents Chemother. **53:**4588–4597.
18. **Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J.** 2006. Assessment of the drug susceptibility of *Plasmodium falciparum* clinical isolates from Africa by using a *Plasmodium* lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob. Agents Chemother. **50:**3343–3349.
19. **Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P.** 2008. In vitro monitoring of *Plasmodium falciparum* drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob. Agents Chemother. **52:**288–298.
20. **Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F.** 2000. *Plasmodium falciparum* antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. **94:**537–544.
21. **Aponte SL, Diaz G, Pava Z, Echeverry DF, Ibarguen D, Rios M, Murcia LM, Quelal C, Murillo C, Gil P, Bjorkman A, Osorio L.** 2011. Sentinel network for monitoring in vitro susceptibility of *Plasmodium falciparum* to antimalarial drugs in Colombia: a proof of concept. Mem. Inst. Oswaldo Cruz **106**(Suppl 1):123–129.
22. **Attlmayr B, Thriemer K, Haque R, Wagatsuma Y, Abdus Salam M, Akhter S, Fukuda M, Schaecher K, Miller RS, Noedl H.** 2006. In vitro antimalarial drug resistance in Southeastern Bangladesh. Wien Klin. Wochenschr **118:**58–61. (In German.)
23. **Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ.** 2010. *In vitro* sensitivities of *Plasmodium falciparum* to different antimalarial drugs in Uganda. Antimicrob. Agents Chemother. **54:**1200–1206.
24. **Sinou V, Quang LH, Pelleau S, Huong VN, Huong NT, Tai LM, Bertaux L, Desbordes M, Latour C, Long LQ, Thanh NX, Parzy D.** 2011. Polymorphism of *Plasmodium falciparum* Na^+/H^+ exchanger is indicative of a low in vitro quinine susceptibility in isolates from Viet Nam. Malar. J. **10:**164. doi:10.1186/1475-2875-10-164.
25. **Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Wade B, Bercion R, Pradines B.** 2011. Ex vivo susceptibility of *Plasmodium falciparum* isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar. J. **10:**310. doi:10.1186/1475-2875-10-310.
26. **Quashie NB, Duah NO, Abuaku B, Koram KA.** 2007. The in-vitro susceptibilities of Ghanaian *Plasmodium falciparum* to antimalarial drugs. Ann. Trop. Med. Parasitol. **101:**391–398.
27. **Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM.** 2012. Artemisinin-resistant *Plasmodium falciparum* in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect. Dis. **12:** 851–858.
28. **Ringwald P, Bickii J, Basco LK.** 1996. In vitro activity of antimalarials against clinical isolates of *Plasmodium falciparum* in Yaounde, Cameroon. Am. J. Trop. Med. Hyg. **55:**254–258.
29. **Lim P, Chim P, Sem R, Nemh S, Poravuth Y, Lim C, Seila S, Tsuyuoka R, Denis MB, Socheat D, Fandeur T.** 2005. In vitro monitoring of *Plasmodium falciparum* susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001–2002. Acta Trop. **93:**31–40.
30. **Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA.** 2006. Decreasing *pfmdr1* copy number in *Plasmodium falciparum* malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. **194:**528–535.
31. **Childs GE, Boudreau EF, Milhous WK, Wimonwattratee T, Pooyindee N, Pang L, Davidson DE, Jr.** 1989. A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of *Plasmodium falciparum*. Am. J. Trop. Med. Hyg. **40:**7–11.
32. **Basco LK, Le Bras J.** 1993. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of *Plasmodium falciparum*. Am. J. Trop. Med. Hyg. **48:**120–125.
33. **Ringwald P, Bickii J, Basco LK.** 1999. In vitro activity of dihydroartemisinin against clinical isolates of *Plasmodium falciparum* in Yaounde, Cameroon. Am. J. Trop. Med. Hyg. **61:**187–192.
34. **Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, Pradines B.** 2011. Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro *Plasmodium falciparum* susceptibility to standard anti-malarial drugs. Malar. J. **10:**8. doi:10.1186/1475-2875-10-8.
35. **Rutvisuttinunt W.** 2012. Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of *Plasmodium falciparum* field isolates. Malar. J. **11:**325. doi:10.1186/1475-2875-11-325.
36. **Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, Lindegardh N.** 2010. Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malar. J. **9:**375. doi:10.1186/1475-2875-9-375.
37. **Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC.** 2007. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob. Agents Chemother. **51:**1926–1933.
38. **Willet GP, Milhous WK, Gerena L, Oduola AM.** 1991. Mixed population dynamics in human malaria parasite cultures. Trans. R. Soc. Trop. Med. Hyg. **85:**33–34.
39. **Geary TG, Divo AA, Jensen JB.** 1989. Stage specific actions of antimalarial drugs on *Plasmodium falciparum* in culture. Am. J. Trop. Med. Hyg. **40:**240–244.
40. **Skinner TS, Manning LS, Johnston WA, Davis TM.** 1996. In vitro stage-specific sensitivity of *Plasmodium falciparum* to quinine and artemisinin drugs. Int. J. Parasitol. **26:**519–525.
41. **ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S.** 1993. *Plasmodium falciparum*: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol. **76:**85–95.
42. **Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Bohme U, Lemieux J, Barrell B, Pain A, Berriman M, Newbold C, Llinas M.** 2010. New insights into the blood-stage transcriptome of *Plasmodium falciparum* using RNA-Seq. Mol. Microbiol. **76:**12–24.
43. **Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, Vial H.** 2010. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J. Clin. Microbiol. **48:**1651–1660.
44. **Murphy S, Watkins WM, Bray PG, Lowe B, Winstanley PA, Peshu N,**

Marsh K. 1995. Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Am. J. Trop. Med. Hyg. **53:**303–305.
45. **Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ.** 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. N. Engl. J. Med. **361:**455–467.
46. **Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F.** 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet **379:**1960–1966.
47. **Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ.** 2011. Intrahost modeling of artemisinin resistance in *Plasmodium falciparum*. Proc. Natl. Acad. Sci. U. S. A. **108:**397–402.
48. **Alin MH, Bjorkman A.** 1994. Concentration and time dependency of artemisinin efficacy against *Plasmodium falciparum* in vitro. Am. J. Trop. Med. Hyg. **50:**771–776.
49. **Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S.** 2006. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of *Plasmodium falciparum*. J. Antimicrob. Chemother. **58:**52–58.
50. **Natalang O, Bischoff E, Deplaine G, Proux C, Dillies MA, Sismeiro O, Guigon G, Bonnefoy S, Patarapotikul J, Mercereau-Puijalon O, Coppee JY, David PH.** 2008. Dynamic RNA profiling in *Plasmodium falciparum* synchronized blood stages exposed to lethal doses of artesunate. BMC Genomics **9:**388. doi:10.1186/1471-2164-9-388.
51. **Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L.** 2011. Artemisinin activity against *Plasmodium falciparum* requires hemoglobin uptake and digestion. Proc. Natl. Acad. Sci. U. S. A. **108:**11405–11410.
52. **Deplaine G, Lavazec C, Bischoff E, Natalang O, Perrot S, Guillotte-Blisnick M, Coppee JY, Pradines B, Mercereau-Puijalon O, David PH.** 2011. Artesunate tolerance in transgenic *Plasmodium falciparum* parasites overexpressing a tryptophan-rich protein. Antimicrob. Agents Chemother. **55:**2576–2584.
53. **Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D.** 2013. Reduced artemisinin susceptibility of *Plasmodium falciparum* ring stages in western Cambodia. Antimicrob. Agents Chemother. **57:**914–923.
54. **Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L.** 2013. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc. Natl. Acad. Sci. U. S. A. **110:**5157–5162.

Parameter	Definition
Growth	Raw measurement of growth, e.g. cpm (hypoxanthine), OD (ELISA) etc.
$G(C_0)$	The mean growth in all wells on a plate which contain no drug (baseline)
$G(C_{max})$	The mean growth in all wells with the highest concentration of a particular drug
G_{min}	The mean growth at the two concentrations ranked as having the lowest mean growth for a particular drug
Reduction	Absolute reduction in growth caused by drug compared to baseline
R_{max1}	$G(C_0) - G(C_{max})$
R_{max2}	$G(C_0) - G_{min}$

Supplementary Table 1: Definitions of growth and growth reduction.

	Odds Ratio	p value	Lower 95%CI	Upper 95% CI
Drug (reference = DHA)				
AS	0.23	<0.001	0.13	0.42
AM	0.84	0.69	0.34	2.04
DQ	2.58	<0.001	2.05	3.23
LUM	2.47	<0.001	1.94	3.15
MQ	2.05	<0.001	1.60	2.61
PIP	2.63	<0.001	1.82	3.82
CQ	1.61	<0.001	1.29	2.00
QN	1.85	<0.001	1.45	2.35
Method (reference = hypoxanthine)				
HRP2	0.66	0.29	0.31	1.42
LDH	1.27	0.007	1.07	1.51
SYBR green	0.36	0.13	0.10	1.35
Microscopy	0.00			

Supplementary Table 2: Risk factors for concentration-inhibition curves showing a paradoxical increase in apparent growth of more than 10% at high drug concentrations, based on fitting a model with drug and method as fixed effects and site as a random effect (due to the heterogeneity between sites). No assays with paradoxical increase were observed in microscopic datasets. Abbreviations: DHA = dihydroartemisinin, AM = artemether, AS = artesunate, CQ = chloroquine, DQ = desethylamodiaquine, LUM = lumefantrine, MQ = mefloquine, PIP = piperaquine, QN = quinine.

Supplementary Table 3: Effect of differing reliability criteria on correlation coefficients and associated data for IC_{50} value comparisons for all drug pairs. Three levels of exclusion criteria were studied: [a]exclusion by default IVART criteria, [b]IVART criteria with additional exclusion of fixed gamma assays with growth ratio 2 - 3 and [c]IVART criteria with additional exclusion of fixed gamma assays with growth ratio 3 - 5. Abbreviations: r = Pearson coefficient, p = p value, n = number of isolates remaining after application of each level of exclusion criteria, (%) = proportion of additional isolates removed by each additional level of exclusion criteria, DHA = dihydroartemisinin, AM = artemether, AS = artesunate, CQ = chloroquine, DQ = desethylamodiaquine, LUM = lumefantrine, MQ = mefloquine, PIP = piperaquine, QN = quinineH = HRP2, Hx = hypoxanthine, L = LDH, M = microscopic.

Drugs	Code	Dataset	ALL DATA			IVART CRITERIA				IVART CRITERIA[b]				IVART CRITERIA[c]			
			r	p	n	r	p	n	Loss (%)	r	p	n	Loss (%)	r	p	n	Loss (%)
AM v AS	C	Fr Guiana	0.701	<0.0001	80	0.743	<0.0001	63	21.25	0.762	<0.0001	62	1.25	0.756	<0.0001	56	7.50
AM v DHA	C	Fr Guiana	0.531	<0.0001	56	0.482	0.0014	41	26.79	0.399	0.0108	40	1.79	0.517	0.0017	34	10.71
AM v LUM	C	Fr Guiana	0.638	<0.0001	82	0.680	<0.0001	60	26.83	0.685	<0.0001	55	6.10	0.653	<0.0001	49	7.32
AM v QN	C	Fr Guiana	0.502	<0.0001	81	0.565	<0.0001	68	16.05	0.609	<0.0001	66	2.47	0.515	<0.0001	58	9.88
AS v DHA	C	Fr Guiana	0.579	<0.0001	56	0.569	0.0002	38	32.14	0.569	0.0002	38	0.00	0.578	0.0002	36	3.57
AS v DHA	D	Thailand-Hx	0.702	<0.0001	39	0.820	<0.0001	37	5.13	0.825	<0.0001	33	10.26	0.803	<0.0001	32	2.56
AS v DHA	F	Bangladesh	0.849	<0.0001	89	0.898	<0.0001	71	20.22	0.896	<0.0001	68	3.37	0.902	<0.0001	64	4.49
AS v DHA	K	Thailand-L	0.880	<0.0001	64	0.784	<0.0001	60	6.25	0.791	<0.0001	59	1.56	0.791	<0.0001	58	1.56
AS v LUM	C	Fr Guiana	0.454	<0.0001	79	0.437	0.0008	56	29.11	0.418	0.0018	53	3.80	0.439	0.0016	49	5.06
AS v LUM	D	Thailand-Hx	0.037	0.8275	38	-0.038	0.8281	35	7.89	-0.016	0.9306	32	7.89	-0.074	0.6944	31	2.63
AS v LUM	K	Thailand-L	0.471	0.0001	62	0.468	0.0005	51	17.74	0.468	0.0005	51	0.00	0.445	0.0012	50	1.61
AS v PIP	D	Thailand-Hx	-0.069	0.6769	39	-0.092	0.5879	37	5.13	-0.060	0.7404	33	10.26	-0.178	0.3304	32	2.56
AS v PIP	K	Thailand-L	0.274	0.0285	64	0.024	0.8606	56	12.50	0.158	0.2492	55	1.56	0.156	0.2638	53	3.13
AS v QN	C	Fr Guiana	0.266	0.0184	78	0.444	0.0003	61	21.79	0.467	0.0002	60	1.28	0.394	0.0026	56	5.13
AS v QN	D	Thailand-Hx	0.348	0.0322	38	0.337	0.0479	35	7.89	0.285	0.1207	31	10.53	0.285	0.1207	31	0.00

AS v QN	F	Bangladesh	0.444	<0.0001	89	0.596	<0.0001	56	37.08	0.522	0.0001	51	5.62	0.520	0.0001	49	2.25
AS v QN	K	Thailand-L	0.439	0.0003	63	0.174	0.2318	49	22.22	0.471	0.0008	47	3.17	0.455	0.0015	46	1.59
AS v QN	N	Ghana	0.266	0.065	49	0.193	0.4012	21	57.14	0.179	0.4636	19	4.08	0.153	0.5577	17	4.08
CQ v AM	C	Fr Guiana	0.399	0.0002	83	0.486	<0.0001	69	16.87	0.494	<0.0001	66	3.61	0.537	<0.0001	59	8.43
CQ v AS	C	Fr Guiana	0.060	0.5981	80	0.180	0.1593	63	21.25	0.194	0.1299	62	1.25	0.277	0.0356	58	5.00
CQ v AS	D	Thailand-Hx	-0.233	0.148	40	-0.351	0.0358	36	10.00	-0.458	0.0083	32	10.00	-0.471	0.0075	31	2.50
CQ v AS	F	Bangladesh	0.391	0.0002	88	0.268	0.0435	57	35.23	0.091	0.5236	51	6.82	0.045	0.7607	49	2.27
CQ v AS	K	Thailand-L	0.451	0.0002	64	-0.006	0.9657	60	6.25	0.022	0.8727	58	3.13	0.024	0.8614	57	1.56
CQ v AS	N	Ghana	-0.025	0.8626	49	0.042	0.8515	22	55.10	0.042	0.8515	22	0.00	0.119	0.6288	19	6.12
CQ v DHA	A	Madagascar	0.255	<0.0001	259	0.394	<0.0001	189	27.03	0.390	<0.0001	181	3.09	0.376	<0.0001	173	3.09
CQ v DHA	B	Travellers-Hx	0.011	0.8432	344	-0.025	0.6743	291	15.41	-0.010	0.8657	283	2.33	-0.005	0.9349	279	1.16
CQ v DHA	C	Fr Guiana	0.001	0.9916	56	-0.005	0.9755	40	28.57	-0.044	0.7885	39	1.79	-0.044	0.7885	39	0.00
CQ v DHA	D	Thailand-Hx	-0.436	0.0055	39	-0.435	0.008	36	7.69	-0.423	0.0114	35	2.56	-0.539	0.0018	31	10.26
CQ v DHA	E	Colombia-H	0.251	0.0694	53	0.374	0.0296	34	35.85	0.269	0.1576	29	9.43	0.143	0.5268	22	13.21
CQ v DHA	F	Bangladesh	0.392	0.0002	88	0.208	0.1171	58	34.09	0.010	0.9444	52	6.82	-0.018	0.9036	50	2.27
CQ v DHA	G	Uganda	0.114	0.3327	74	0.366	0.022	39	47.30	0.410	0.0145	35	5.41	0.435	0.0183	29	8.11
CQ v DHA	H	Vietnam	0.018	0.9066	46	-0.066	0.7324	29	36.96	0.090	0.6495	28	2.17	0.121	0.5468	27	2.17
CQ v DHA	I	Senegal	-0.034	0.7807	68	-0.034	0.8107	52	23.53	0.132	0.3976	43	13.24	0.100	0.546	39	5.88
CQ v DHA	J	Travellers-L	-0.108	0.1625	170	-0.142	0.1037	133	21.76	-0.154	0.0799	130	1.76	-0.178	0.0458	126	2.35
CQ v DHA	K	Thailand-L	0.401	0.001	64	-0.014	0.9112	63	1.56	0.003	0.9809	60	4.69	0.004	0.9758	59	1.56
CQ v DHA	L	Cambodia	0.049	0.7175	56	0.138	0.4072	38	32.14	0.092	0.5989	35	5.36	0.032	0.8603	32	5.36
CQ v DHA	M	Colombia-M	-0.017	0.9329	28	0.162	0.4302	26	7.14	0.162	0.4302	26	0.00	0.162	0.4302	26	0.00
CQ v DQ	A	Madagascar	0.526	<0.0001	265	0.563	<0.0001	201	24.15	0.566	<0.0001	193	3.02	0.568	<0.0001	184	3.40
CQ v DQ	B	Travellers-Hx	0.658	<0.0001	341	0.840	<0.0001	288	15.54	0.872	<0.0001	279	2.64	0.876	<0.0001	278	0.29
CQ v DQ	E	Colombia-H	0.473	0.0003	54	0.923	<0.0001	28	48.15	0.831	<0.0001	19	16.67	0.748	0.0033	13	11.11
CQ v DQ	G	Uganda	0.137	0.2721	66	0.185	0.329	30	54.55	0.556	0.0058	23	10.61	0.405	0.0956	18	7.58
CQ v DQ	H	Vietnam	0.529	0.0002	46	0.697	0.0002	24	47.83	0.632	0.0021	21	6.52	0.647	0.0021	20	2.17
CQ v DQ	I	Senegal	0.575	<0.0001	67	0.657	<0.0001	49	26.87	0.723	<0.0001	43	8.96	0.727	<0.0001	36	10.45
CQ v DQ	J	Travellers-L	0.764	<0.0001	182	0.834	<0.0001	147	19.23	0.861	<0.0001	128	10.44	0.864	<0.0001	106	12.09
CQ v DQ	M	Colombia-M	0.727	0.0033	14	0.732	0.0105	11	21.43	0.732	0.0105	11	0.00	0.732	0.0105	11	0.00

CQ v LUM	B	Travellers-Hx	-0.092	0.1476	247	-0.134	0.0565	203	17.81	-0.129	0.0686	200	1.21	-0.157	0.0276	197	1.21
CQ v LUM	C	Fr Guiana	0.493	<0.0001	82	0.557	<0.0001	62	24.39	0.526	<0.0001	57	6.10	0.538	<0.0001	55	2.44
CQ v LUM	D	Thailand-Hx	-0.007	0.9667	39	-0.063	0.7178	35	10.26	-0.083	0.6393	34	2.56	-0.065	0.7224	32	5.13
CQ v LUM	G	Uganda	0.099	0.4105	72	-0.064	0.6784	45	37.50	0.032	0.8488	38	9.72	0.058	0.7501	33	6.94
CQ v LUM	H	Vietnam	-0.208	0.1653	46	-0.340	0.1043	24	47.83	-0.339	0.1141	23	2.17	-0.339	0.1141	23	0.00
CQ v LUM	I	Senegal	-0.148	0.2366	66	-0.139	0.3222	53	19.70	-0.217	0.163	43	15.15	-0.241	0.1576	36	10.61
CQ v LUM	J	Travellers-L	-0.226	0.0041	160	-0.231	0.0075	133	16.88	-0.252	0.004	129	2.50	-0.243	0.0067	124	3.13
CQ v LUM	K	Thailand-L	0.221	0.0841	62	-0.043	0.7632	52	16.13	-0.005	0.9739	50	3.23	-0.005	0.9739	50	0.00
CQ v MQ	A	Madagascar	0.061	0.4585	151	0.132	0.1568	117	22.52	0.122	0.201	111	3.97	0.169	0.0853	105	3.97
CQ v MQ	B	Travellers-Hx	-0.010	0.9107	137	0.064	0.4889	118	13.87	0.061	0.517	116	1.46	0.083	0.3805	114	1.46
CQ v MQ	C	Fr Guiana	0.414	0.0002	77	0.555	<0.0001	57	25.97	0.576	<0.0001	55	2.60	0.633	<0.0001	51	5.19
CQ v MQ	D	Thailand-Hx	-0.020	0.9033	41	-0.154	0.3695	36	12.20	-0.154	0.3695	36	0.00	-0.178	0.3232	33	7.32
CQ v MQ	E	Colombia-H	0.510	0.0001	55	0.555	0.006	23	58.18	0.605	0.0037	21	3.64	0.552	0.0117	20	1.82
CQ v MQ	F	Bangladesh	0.140	0.1937	88	0.008	0.9544	50	43.18	-0.114	0.4733	42	9.09	-0.133	0.4134	40	2.27
CQ v MQ	H	Vietnam	0.035	0.8158	46	-0.190	0.3731	24	47.83	-0.280	0.2076	22	4.35	-0.286	0.2097	21	2.17
CQ v MQ	I	Senegal	0.171	0.1641	68	0.182	0.1966	52	23.53	0.200	0.1776	47	7.35	0.053	0.7532	38	13.24
CQ v MQ	J	Travellers-L	0.167	0.3046	40	0.154	0.418	30	25.00	0.174	0.3673	29	2.50	0.161	0.4135	28	2.50
CQ v MQ	K	Thailand-L	0.164	0.2034	62	-0.089	0.5655	44	29.03	-0.098	0.5407	41	4.84	-0.098	0.5407	41	0.00
CQ v MQ	L	Cambodia	-0.034	0.8055	55	-0.115	0.4991	37	32.73	-0.186	0.3093	32	9.09	-0.174	0.3662	29	5.45
CQ v MQ	M	Colombia-M	0.289	0.1279	29	0.282	0.1549	27	6.90	0.282	0.1549	27	0.00	0.282	0.1549	27	0.00
CQ v MQ	N	Ghana	-0.001	0.9929	49	-0.079	0.7393	20	59.18	-0.079	0.7393	20	0.00	-0.177	0.4831	18	4.08
CQ v PIP	D	Thailand-Hx	0.309	0.056	39	0.378	0.0229	36	7.69	0.378	0.0229	36	0.00	0.442	0.0101	33	7.69
CQ v PIP	G	Uganda	-0.008	0.9454	73	-0.024	0.8753	45	38.36	-0.011	0.9527	34	15.07	-0.169	0.4203	25	12.33
CQ v PIP	H	Vietnam	0.012	0.9357	46	-0.026	0.8949	29	36.96	-0.048	0.8075	28	2.17	0.090	0.6607	26	4.35
CQ v PIP	K	Thailand-L	0.395	0.0012	64	0.214	0.1035	59	7.81	0.275	0.0388	57	3.13	0.274	0.0407	56	1.56
CQ v QN	A	Madagascar	0.435	<0.0001	255	0.356	<0.0001	187	26.67	0.403	<0.0001	181	2.35	0.393	<0.0001	169	4.71
CQ v QN	B	Travellers-Hx	0.332	0.0001	134	0.424	<0.0001	119	11.19	0.515	<0.0001	114	3.73	0.537	0	110	2.99
CQ v QN	C	Fr Guiana	0.403	0.0002	81	0.486	<0.0001	67	17.28	0.494	<0.0001	64	3.70	0.451	0.0003	61	3.70
CQ v QN	D	Thailand-Hx	0.008	0.9639	39	-0.025	0.8869	35	10.26	-0.026	0.8867	33	5.13	-0.017	0.926	32	2.56
CQ v QN	F	Bangladesh	0.445	<0.0001	88	0.532	<0.0001	52	40.91	0.521	0.0002	46	6.82	0.508	0.0004	45	1.14
CQ v QN	G	Uganda	0.349	0.0022	75	0.419	0.0034	47	37.33	0.629	<0.0001	38	12.00	0.551	0.0024	28	13.33
CQ v QN	H	Vietnam	0.533	0.0001	46	0.464	0.0128	28	39.13	0.481	0.0151	25	6.52	0.480	0.0176	24	2.17

CQ v QN	I	Senegal	0.236	0.0561	66	0.227	0.106	52	21.21	0.252	0.1222	39	19.70	0.265	0.1189	36	4.55
CQ v QN	J	Travellers-L	0.534	0.0003	42	0.535	0.0023	30	28.57	0.492	0.0068	29	2.38	0.572	0.0018	27	4.76
CQ v QN	K	Thailand-L	0.574	<0.0001	63	0.485	0.0003	51	19.05	0.118	0.4305	47	6.35	0.118	0.4305	47	0.00
CQ v QN	L	Cambodia	0.377	0.0041	56	0.330	0.0431	38	32.14	0.317	0.0597	36	3.57	0.317	0.0776	32	7.14
CQ v QN	N	Ghana	0.511	0.0002	49	0.467	0.0283	22	55.10	0.389	0.0898	20	4.08	0.437	0.0798	17	6.12
DHA v DQ	A	Madagascar	0.136	0.0289	259	0.124	0.0751	208	19.69	0.151	0.0341	198	3.86	0.121	0.0967	189	3.47
DHA v DQ	B	Travellers-Hx	0.216	0.0001	326	0.193	0.0011	284	12.88	0.185	0.0021	276	2.45	0.185	0.0021	276	0.00
DHA v DQ	E	Colombia-H	0.374	0.0063	52	0.167	0.4138	26	50.00	0.136	0.5791	19	13.46	0.369	0.2144	13	11.54
DHA v DQ	G	Uganda	0.321	0.0086	66	0.029	0.8717	33	50.00	0.175	0.3555	30	4.55	0.205	0.3253	25	7.58
DHA v DQ	H	Vietnam	0.032	0.832	47	0.108	0.5619	31	34.04	0.110	0.5783	28	6.38	0.110	0.5783	28	0.00
DHA v DQ	I	Senegal	0.248	0.0396	69	0.309	0.029	50	27.54	0.115	0.4586	44	8.70	0.128	0.4511	37	10.14
DHA v DQ	J	Travellers-L	-0.001	0.9914	172	-0.039	0.6554	135	21.51	-0.046	0.6232	119	9.30	-0.043	0.6636	105	8.14
DHA v DQ	M	Colombia-M	-0.202	0.5091	13	-0.209	0.538	11	15.38	-0.209	0.538	11	0.00	-0.209	0.538	11	0.00
DHA v LUM	B	Travellers-Hx	0.271	<0.0001	245	0.471	<0.0001	206	15.92	0.462	<0.0001	204	0.82	0.462	0	203	0.41
DHA v LUM	C	Fr Guiana	0.281	0.0361	56	0.245	0.1322	39	30.36	0.049	0.7752	36	5.36	0.049	0.7752	36	0.00
DHA v LUM	D	Thailand-Hx	0.251	0.1228	39	0.223	0.199	35	10.26	0.186	0.3003	33	5.13	0.168	0.3678	31	5.13
DHA v LUM	G	Uganda	0.160	0.1806	72	-0.050	0.7482	44	38.89	-0.015	0.9281	41	4.17	-0.016	0.927	36	6.94
DHA v LUM	H	Vietnam	0.115	0.4381	48	0.336	0.0483	35	27.08	0.366	0.0334	34	2.08	0.366	0.0334	34	0.00
DHA v LUM	I	Senegal	0.375	0.0016	68	0.412	0.0018	55	19.12	0.402	0.0046	48	10.29	0.398	0.0062	46	2.94
DHA v LUM	J	Travellers-L	0.232	0.0041	151	0.266	0.0031	122	19.21	0.297	0.001	120	1.32	0.302	0.0009	118	1.32
DHA v LUM	K	Thailand-L	0.282	0.0263	62	0.136	0.3373	52	16.13	0.136	0.3373	52	0.00	0.120	0.4022	51	1.61
DHA v PIP	D	Thailand-Hx	-0.006	0.9709	40	0.041	0.8068	38	5.00	0.040	0.8169	36	5.00	-0.030	0.8704	32	10.00
DHA v PIP	G	Uganda	0.438	0.0001	73	0.527	0.0001	49	32.88	0.601	<0.0001	40	12.33	0.694	0	31	12.33
DHA v PIP	H	Vietnam	0.185	0.208	48	-0.051	0.7594	39	18.75	-0.051	0.7594	39	0.00	-0.051	0.7594	39	0.00
DHA v PIP	K	Thailand-L	0.481	0.0001	64	0.376	0.0034	59	7.81	0.446	0.0005	57	3.13	0.447	0.0006	55	3.13
DHA v QN	A	Madagascar	0.300	<0.0001	253	0.223	0.002	190	24.90	0.302	<0.0001	182	3.16	0.301	0.0001	171	4.35
DHA v QN	B	Travellers-Hx	0.159	0.0696	131	0.120	0.2048	113	13.74	0.112	0.2485	108	3.82	0.103	0.2965	105	2.29
DHA v QN	C	Fr Guiana	0.179	0.186	56	0.133	0.4071	41	26.79	0.166	0.3058	40	1.79	0.166	0.3058	40	0.00
DHA v QN	D	Thailand-Hx	0.550	0.0003	38	0.557	0.0005	35	7.89	0.501	0.0035	32	7.89	0.503	0.0039	31	2.63
DHA v QN	F	Bangladesh	0.441	<0.0001	89	0.497	0.0001	57	35.96	0.425	0.0019	51	6.74	0.452	0.0011	49	2.25
DHA v QN	G	Uganda	0.351	0.002	75	0.476	0.0009	45	40.00	0.428	0.0053	41	5.33	0.344	0.0624	30	14.67

DHA v QN	H	Vietnam	0.081	0.5884	47	-0.028	0.8709	36	23.40	-0.021	0.9042	35	2.13	-0.021	0.9042	35	0.00
DHA v QN	I	Senegal	0.370	0.0019	68	0.302	0.025	55	19.12	0.185	0.213	47	11.76	0.194	0.1954	46	1.47
DHA v QN	J	Travellers-L	0.047	0.7779	39	-0.014	0.9422	28	28.21	0.049	0.8105	26	5.13	0.143	0.5064	24	5.13
DHA v QN	K	Thailand-L	0.443	0.0003	63	0.180	0.2055	51	19.05	0.439	0.0016	49	3.17	0.434	0.0021	48	1.59
DHA v QN	L	Cambodia	0.473	0.0002	56	0.559	0.0001	41	26.79	0.552	0.0002	40	1.79	0.526	0.0007	38	3.57
DQ v LUM	B	Travellers-Hx	-0.046	0.4869	235	-0.040	0.5762	198	15.74	-0.040	0.5762	198	0.00	-0.040	0.5817	197	0.43
DQ v LUM	G	Uganda	-0.001	0.9965	66	-0.237	0.1587	37	43.94	-0.425	0.0172	31	9.09	-0.456	0.0193	26	7.58
DQ v LUM	H	Vietnam	0.107	0.4762	47	0.065	0.7413	28	40.43	0.041	0.8543	23	10.64	0.041	0.8543	23	0.00
DQ v LUM	I	Senegal	0.110	0.3722	68	0.156	0.2614	54	20.59	0.123	0.4088	47	10.29	0.077	0.6413	39	11.76
DQ v LUM	J	Travellers-L	-0.173	0.029	159	-0.249	0.0042	130	18.24	-0.244	0.0086	115	9.43	-0.233	0.0212	98	10.69
DQ v PIP	G	Uganda	0.006	0.9623	65	0.133	0.4479	35	46.15	0.300	0.1206	28	10.77	0.006	0.9802	20	12.31
DQ v PIP	H	Vietnam	0.176	0.2365	47	0.289	0.1093	32	31.91	0.330	0.0859	28	8.51	0.367	0.0596	27	2.13
DQ v QN	A	Madagascar	0.234	0.0001	259	0.102	0.1478	203	21.62	0.108	0.1377	191	4.63	0.087	0.2509	178	5.02
DQ v QN	B	Travellers-Hx	0.439	<0.0001	130	0.466	<0.0001	117	10.00	0.501	<0.0001	113	3.08	0.534	0	111	1.54
DQ v QN	G	Uganda	0.010	0.9347	67	0.198	0.2535	35	47.76	0.296	0.1129	30	7.46	0.341	0.0956	25	7.46
DQ v QN	H	Vietnam	0.308	0.0353	47	0.213	0.2676	29	38.30	0.255	0.2181	25	8.51	0.255	0.2181	25	0.00
DQ v QN	I	Senegal	0.387	0.0011	68	0.554	<0.0001	52	23.53	0.540	0.0001	45	10.29	0.511	0.0009	39	8.82
DQ v QN	J	Travellers-L	0.644	<0.0001	39	0.677	<0.0001	31	20.51	0.697	0.0001	27	10.26	0.795	0	21	15.38
LUM v PIP	D	Thailand-Hx	-0.018	0.914	39	-0.045	0.7963	35	10.26	-0.004	0.9822	34	2.56	-0.048	0.7956	32	5.13
LUM v PIP	G	Uganda	-0.140	0.2451	71	-0.314	0.028	49	30.99	-0.471	0.0019	41	11.27	-0.520	0.0019	33	11.27
LUM v PIP	H	Vietnam	0.309	0.0329	48	0.082	0.6384	35	27.08	0.074	0.6768	34	2.08	0.074	0.6768	34	0.00
LUM v PIP	K	Thailand-L	0.182	0.1568	62	0.236	0.1059	48	22.58	0.236	0.1059	48	0.00	0.236	0.1059	48	0.00
LUM v QN	B	Travellers-Hx	-0.139	0.1469	111	0.054	0.5982	98	11.71	0.096	0.3595	94	3.60	0.077	0.4668	91	2.70
LUM v QN	C	Fr Guiana	0.569	<0.0001	80	0.556	<0.0001	60	25.00	0.614	<0.0001	56	5.00	0.593	0	53	3.75
LUM v QN	D	Thailand-Hx	0.482	0.0019	39	0.654	<0.0001	35	10.26	0.636	0.0001	33	5.13	0.636	0.0001	33	0.00
LUM v QN	G	Uganda	0.474	<0.0001	73	0.280	0.0465	51	30.14	0.209	0.1641	46	6.85	0.239	0.1549	37	12.33
LUM v QN	H	Vietnam	-0.222	0.1342	47	0.211	0.2634	30	36.17	0.221	0.2485	29	2.13	0.221	0.2485	29	0.00
LUM v QN	I	Senegal	0.484	<0.0001	68	0.550	<0.0001	57	16.18	0.531	0.0001	46	16.18	0.537	0.0002	44	2.94
LUM v QN	J	Travellers-L	0.009	0.9574	36	-0.009	0.9615	29	19.44	-0.024	0.9058	26	8.33	0.012	0.9563	24	5.56

LUM v QN	K	Thailand-L	0.487	0.0001	62	0.534	0.0002	45	27.42	0.526	0.0002	44	1.61	0.526	0.0002	44	0.00
MQ v AM	C	Fr Guiana	0.485	<0.0001	77	0.533	<0.0001	59	23.38	0.549	<0.0001	57	2.60	0.518	0.0001	52	6.49
MQ v AS	C	Fr Guiana	0.584	<0.0001	77	0.595	<0.0001	58	24.68	0.599	<0.0001	57	1.30	0.605	0	51	7.79
MQ v AS	D	Thailand-Hx	0.398	0.0111	40	0.369	0.0269	36	10.00	0.366	0.0361	33	7.50	0.403	0.0247	31	5.00
MQ v AS	F	Bangladesh	0.415	0.0001	89	0.424	0.0014	54	39.33	0.221	0.1392	46	8.99	0.029	0.854	42	4.49
MQ v AS	K	Thailand-L	0.482	0.0001	62	0.663	<0.0001	43	30.65	0.626	<0.0001	42	1.61	0.626	0	42	0.00
MQ v AS	N	Ghana	0.599	<0.0001	49	0.571	0.0056	22	55.10	0.571	0.0056	22	0.00	0.571	0.0056	22	0.00
MQ v DHA	A	Madagascar	0.190	0.0218	146	0.359	0.0001	118	19.18	0.400	<0.0001	113	3.42	0.353	0.0002	106	4.79
MQ v DHA	B	Travellers-Hx	0.571	<0.0001	132	0.632	<0.0001	112	15.15	0.631	<0.0001	111	0.76	0.642	0	110	0.76
MQ v DHA	C	Fr Guiana	0.393	0.0033	54	0.267	0.1275	34	37.04	0.256	0.1507	33	1.85	0.324	0.075	31	3.70
MQ v DHA	D	Thailand-Hx	0.407	0.0091	40	0.546	0.0006	36	10.00	0.553	0.0006	35	2.50	0.621	0.0002	31	10.00
MQ v DHA	E	Colombia-H	0.582	<0.0001	54	0.528	0.0067	25	53.70	0.465	0.0253	23	3.70	0.481	0.0372	19	7.41
MQ v DHA	F	Bangladesh	0.353	0.0007	89	0.403	0.0019	57	35.96	0.300	0.0364	49	8.99	0.221	0.1409	46	3.37
MQ v DHA	H	Vietnam	0.097	0.5168	47	-0.112	0.5479	31	34.04	-0.209	0.2669	30	2.13	-0.209	0.2669	30	0.00
MQ v DHA	I	Senegal	0.247	0.0292	78	0.397	0.0013	63	19.23	0.491	0.0001	59	5.13	0.554	0	56	3.85
MQ v DHA	J	Travellers-L	0.171	0.2983	39	0.303	0.1103	29	25.64	0.303	0.1103	29	0.00	0.318	0.099	28	2.56
MQ v DHA	K	Thailand-L	0.493	<0.0001	62	0.505	0.0005	44	29.03	0.454	0.0022	43	1.61	0.454	0.0022	43	0.00
MQ v DHA	L	Cambodia	0.432	0.001	55	0.293	0.0593	42	23.64	0.236	0.1604	37	9.09	0.236	0.1604	37	0.00
MQ v DHA	M	Colombia-M	0.526	0.0024	31	0.600	0.0007	28	9.68	0.600	0.0007	28	0.00	0.600	0.0007	28	0.00
MQ v DQ	A	Madagascar	0.250	0.0018	153	0.409	<0.0001	126	17.65	0.396	<0.0001	122	2.61	0.403	0	114	5.23
MQ v DQ	B	Travellers-Hx	0.161	0.0636	133	0.203	0.0292	115	13.53	0.203	0.0292	115	0.00	0.203	0.0292	115	0.00
MQ v DQ	E	Colombia-H	0.599	<0.0001	54	0.450	0.0533	19	64.81	0.493	0.0616	15	7.41	0.379	0.2245	12	5.56
MQ v DQ	H	Vietnam	0.450	0.0015	47	0.132	0.5385	24	48.94	0.031	0.897	20	8.51	0.031	0.897	20	0.00
MQ v DQ	I	Senegal	0.392	0.0009	69	0.339	0.014	52	24.64	0.297	0.0401	48	5.80	0.298	0.0616	40	11.59
MQ v DQ	J	Travellers-L	0.193	0.2401	39	0.127	0.51	29	25.64	0.227	0.2744	25	10.26	0.350	0.13	20	12.82
MQ v DQ	M	Colombia-M	0.109	0.7239	13	-0.086	0.8266	9	30.77	-0.086	0.8266	9	0.00	-0.086	0.8266	9	0.00
MQ v LUM	B	Travellers-Hx	0.312	0.0009	111	0.785	<0.0001	95	14.41	0.785	<0.0001	95	0.00	0.786	0	94	0.90
MQ v LUM	C	Fr Guiana	0.532	<0.0001	77	0.593	<0.0001	53	31.17	0.596	<0.0001	50	3.90	0.623	0	45	6.49
MQ v LUM	D	Thailand-Hx	0.730	<0.0001	40	0.742	<0.0001	36	10.00	0.729	<0.0001	35	2.50	0.692	0	33	5.00

MQ v LUM	H	Vietnam	0.047	0.7554	47	0.365	0.0671	26	44.68	0.365	0.0727	25	2.13	0.365	0.0727	25	0.00
MQ v LUM	I	Senegal	0.450	0.0001	68	0.541	<0.0001	57	16.18	0.471	0.0004	53	5.88	0.630	0	49	5.88
MQ v LUM	J	Travellers-L	0.279	0.0999	36	0.261	0.1894	27	25.00	0.227	0.2763	25	5.56	0.213	0.3188	24	2.78
MQ v LUM	K	Thailand-L	0.412	0.001	61	0.719	<0.0001	42	31.15	0.799	<0.0001	41	1.64	0.799	0	41	0.00
MQ v PIP	D	Thailand-Hx	-0.047	0.7736	40	-0.079	0.6453	36	10.00	-0.079	0.6453	36	0.00	-0.104	0.5703	32	10.00
MQ v PIP	H	Vietnam	0.103	0.4899	47	0.319	0.0859	30	36.17	0.319	0.0859	30	0.00	0.152	0.4304	29	2.13
MQ v PIP	K	Thailand-L	0.122	0.3447	62	0.136	0.4013	40	35.48	0.189	0.2565	38	3.23	0.189	0.2565	38	0.00
MQ v QN	A	Madagascar	-0.073	0.3821	147	0.262	0.0056	111	24.49	0.235	0.0146	107	2.72	0.248	0.0117	103	2.72
MQ v QN	B	Travellers-Hx	0.216	0.009	145	0.234	0.0072	131	9.66	0.261	0.0028	129	1.38	0.250	0.0047	126	2.07
MQ v QN	C	Fr Guiana	0.271	0.0187	75	0.488	0.0002	55	26.67	0.518	0.0001	54	1.33	0.484	0.0004	49	6.67
MQ v QN	D	Thailand-Hx	0.572	0.0001	40	0.749	<0.0001	36	10.00	0.748	<0.0001	34	5.00	0.748	0	34	0.00
MQ v QN	F	Bangladesh	0.405	0.0001	89	0.486	0.0003	51	42.70	0.432	0.0043	42	10.11	0.312	0.0504	40	2.25
MQ v QN	H	Vietnam	0.204	0.1686	47	0.133	0.5003	28	40.43	0.333	0.0962	26	4.26	0.333	0.0962	26	0.00
MQ v QN	I	Senegal	0.438	0.0002	68	0.535	<0.0001	58	14.71	0.461	0.0008	50	11.76	0.489	0.0005	47	4.41
MQ v QN	J	Travellers-L	0.499	0.0014	38	0.491	0.0069	29	23.68	0.526	0.0058	26	7.89	0.636	0.0011	23	7.89
MQ v QN	K	Thailand-L	0.641	<0.0001	62	0.762	<0.0001	41	33.87	0.700	<0.0001	39	3.23	0.700	0	39	0.00
MQ v QN	L	Cambodia	0.616	<0.0001	55	0.648	<0.0001	41	25.45	0.622	<0.0001	37	7.27	0.622	0	37	0.00
MQ v QN	N	Ghana	0.516	0.0001	49	0.667	0.0005	23	53.06	0.574	0.0102	19	8.16	0.472	0.0558	17	4.08
PIP v QN	D	Thailand-Hx	0.076	0.6522	38	0.138	0.4306	35	7.89	0.097	0.5927	33	5.26	0.099	0.5893	32	2.63
PIP v QN	G	Uganda	0.030	0.8024	74	-0.067	0.6432	50	32.43	0.082	0.6118	41	12.16	-0.196	0.3183	28	17.57
PIP v QN	H	Vietnam	-0.069	0.6474	47	0.030	0.861	37	21.28	0.279	0.0992	36	2.13	0.279	0.0992	36	0.00
PIP v QN	K	Thailand-L	0.237	0.0616	63	0.136	0.3608	47	25.40	0.180	0.2424	44	4.76	0.177	0.2558	43	1.59

Supplementary Figure Legends

Supplementary Figure 1

Proportion of assays (gamma correctly modelled) with wide confidence interval ratios for IC_{50} estimates (CIR > 3), according to growth ratio. The total proportion of each dataset with wide confidence intervals is shown by the dotted line. Datasets are as indicated in Table 1 and were derived by measurement of hypoxanthine incorporation (A-D), HRP2 (E-H), LDH (I-K) or SYBR Green (L).

Supplementary Figure 2

Illustration of how isolates are excluded by differing levels of criteria in inter-drug correlation analyses of hypoxanthine-based datasets. Log-transformed nM IC_{50} values of mefloquine (MQ) are plotted against those of quinine (QN) for datasets A-D as indicated in the upper part of the figure; chloroquine-desethylamodiaquine (CQ-DQ) correlations for datasets A and B are shown in the lower part. White circles indicate isolates where one or both IC_{50} values are excluded by default IVART criteria. Grey circles indicate isolates where both IC_{50} values for the drug-pair would be accepted as reliable by the default criteria of IVART, but where one or both IC_{50} values were derived by a 1-parameter (fixed gamma) model and had a growth ratio of 2 - 3 (light grey circles) or 3 - 5 (dark grey circles). Black circles indicate isolates accepted as reliable even by the most restrictive criteria: IC_{50} confidence interval ratio less than 3 (2-parameter models) or growth ratio greater than 5 (1-parameter models). The regression lines shown were calculated using data passing default IVART criteria. Summary data for these datasets are shown in Supplementary Table 3.



ScEYEnce Studios
ASM Journals
AAC02350-12
Dr. Woodrow
Figure: Supp. 01



ScEYEnce Studios
ASM Journals
AAC02350-12
Dr. Woodrow
Figure: Supp. 02